180 related articles for article (PubMed ID: 28327188)
21. Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims.
Singh JA; Yu S
Arthritis Res Ther; 2016 Sep; 18(1):209. PubMed ID: 27655429
[TBL] [Abstract][Full Text] [Related]
22. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study.
Shih HJ; Kao MC; Tsai PS; Fan YC; Huang CJ
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):328-333. PubMed ID: 28398294
[TBL] [Abstract][Full Text] [Related]
23. Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly.
Franchi C; Salerno F; Conca A; Djade CD; Tettamanti M; Pasina L; Corrao S; Marengoni A; Marcucci M; Mannucci PM; Nobili A;
Eur J Intern Med; 2014 Nov; 25(9):847-52. PubMed ID: 25439099
[TBL] [Abstract][Full Text] [Related]
24. Frequency and risk factors of gout flares in a large population-based cohort of incident gout.
Rothenbacher D; Primatesta P; Ferreira A; Cea-Soriano L; Rodríguez LA
Rheumatology (Oxford); 2011 May; 50(5):973-81. PubMed ID: 21228059
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis.
Singh JA; Cleveland JD
Arthritis Res Ther; 2018 Aug; 20(1):167. PubMed ID: 30075731
[TBL] [Abstract][Full Text] [Related]
26. The risk of polymyalgia rheumatica in older adults with gout: a Medicare claims study.
Singh JA; Cleveland JD
Rheumatol Adv Pract; 2018; 2(2):rky024. PubMed ID: 31431970
[TBL] [Abstract][Full Text] [Related]
27. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
28. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
29. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G
Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
31. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A
Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941
[TBL] [Abstract][Full Text] [Related]
32. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
33. [The predictive value for major arrhythmic events of ventricular arrhythmias, particularly nonsustained ventricular tachycardias, in the subacute phase of a fibrinolyzed infarct. An analysis of GISSI-2 data. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].
Giani P; Avanzini F; Bagliani G; Galati A; Pucci P; Santoro E
G Ital Cardiol; 1995 Jan; 25(1):77-87. PubMed ID: 7642014
[TBL] [Abstract][Full Text] [Related]
34. Allopurinol adherence and its predictors in gout: a national cohort study in US veterans.
Singh JA; Richman J; Yang S; Bridges SL; Saag K
Lancet Rheumatol; 2020 May; 2(5):e281-e291. PubMed ID: 33215163
[TBL] [Abstract][Full Text] [Related]
35. Factors associated with recurrent hospital admissions for gout: a case-control study.
Hutton I; Gamble G; Gow P; Dalbeth N
J Clin Rheumatol; 2009 Sep; 15(6):271-4. PubMed ID: 19734730
[TBL] [Abstract][Full Text] [Related]
36. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
37. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR
J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767
[TBL] [Abstract][Full Text] [Related]
38. Allopurinol adherence among patients with gout: an Italian general practice database study.
Mantarro S; Capogrosso-Sansone A; Tuccori M; Blandizzi C; Montagnani S; Convertino I; Antonioli L; Fornai M; Cricelli I; Pecchioli S; Cricelli C; Lapi F
Int J Clin Pract; 2015 Jul; 69(7):757-65. PubMed ID: 25683693
[TBL] [Abstract][Full Text] [Related]
39. Opportunities for improving medication use and monitoring in gout.
Singh JA; Hodges JS; Asch SM
Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
[TBL] [Abstract][Full Text] [Related]
40. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
